Levetiracetam

Introduction Overview

Generic Name

levetiracetam

Brand Name

Keppra XR

Dosage Form

Extended-release tablet

Drug Class

Pyrrolidine anticonvulsants

Pharmacokinetics

Absorption:
Levetiracetam is rapidly and almost completely absorbed after oral administration, with a bioavailability close to 100%. The extended-release formulation (Keppra XR) maintains a steady plasma concentration by releasing the drug gradually over time, allowing once-daily dosing. Peak plasma concentrations with the XR tablet are typically reached approximately 4 to 5 hours post-dose, compared to 1 hour for immediate-release tablets. Food does not significantly affect the absorption rate or extent for either formulation, allowing flexibility in administration with or without food. Clinical studies have demonstrated consistent absorption in both pediatric and adult populations, providing predictability in dosing.

Distribution:
Levetiracetam exhibits low plasma protein binding (<10%), which minimizes the risk of displacement interactions with other highly protein-bound drugs. The volume of distribution (Vd) approximates total body water (0.5–0.7 L/kg), reflecting good distribution into body tissues. Notably, levetiracetam crosses the blood-brain barrier effectively, achieving therapeutic concentrations within the central nervous system which is critical for its anticonvulsant efficacy. Studies demonstrate measurable cerebrospinal fluid concentrations at about 50% of plasma levels. Distribution is not significantly altered in elderly patients but may require dose adjustment in renal impairment.

Metabolism:
Levetiracetam undergoes minimal hepatic metabolism, with approximately 24% metabolized primarily via enzymatic hydrolysis of the acetamide group to an inactive carboxylic acid metabolite (ucb L057). This metabolic pathway is independent of the cytochrome P450 enzyme system, reducing the potential for drug-drug interactions. No active metabolites have been identified. This metabolic profile contributes to the drug's favorable safety and tolerability profile, particularly in patients with polypharmacy. The metabolic pathways are consistent across age groups and do not significantly change with hepatic impairment, though clinical caution is advised.

Elimination:
The drug and its metabolites are primarily eliminated via renal excretion, with around 66% excreted unchanged in the urine. The elimination half-life averages 6-8 hours in healthy adults but is prolonged in patients with renal impairment, necessitating dosage adjustments to prevent accumulation. Renal clearance correlates closely with creatinine clearance. Hemodialysis effectively removes levetiracetam from plasma, which is clinically relevant in patients undergoing dialysis. Elimination is not significantly affected by age or hepatic function. Dosing modifications based on renal function are critical to maintain therapeutic levels and minimize adverse effects.

Dosage Forms

Available Dosage Forms:
- Extended-release tablet (Keppra XR) available in strengths of 500 mg and 750 mg (typical dosing leads to use around these strengths; 1000 mg strength in some formulations for other brands).
- Immediate-release tablets (Keppra): 250 mg, 500 mg, 750 mg, and 1000 mg tablets.
- Tablet for suspension (Spritam®): 250 mg, 500 mg, 750 mg, and 1000 mg formulated as rapidly disintegrating oral tablets for ease of swallowing.
- Oral solution (Keppra solution): 100 mg/mL concentration.

Dosages for Adults and Adolescents:
- Keppra XR extended-release tablets for partial-onset seizures in adults and children aged 12 years and older weighing 50 kg or more: Starting dose of 1000 mg once daily, titrated up to a maximum of 3000 mg per day as per clinical response.
- Immediate-release tablets or oral solution for partial-onset seizures:
- Adults and children 16 years and older: starting at 500 mg twice daily, with titration to a maximum of 3000 mg/day.
- Juvenile myoclonic seizures (children 12 years and older): similar dosing to partial-onset seizures.
- Pediatric dosing is weight-based, starting typically at 10 mg/kg twice daily for children aged 4 to 15 years, with maximum doses up to 60 mg/kg/day depending on seizure type.
- Younger children and infants down to 1 month have specific weight-based dosing with lower initial doses and careful titration.

Specific Patient Populations:
- Pediatric patients under 12 years of age should use Keppra XR only under strict medical supervision; safety and efficacy are not established for certain age groups.
- Elderly patients may require dose adjustments due to possible decreased renal function.
- Patients with renal impairment require careful dose reduction based on creatinine clearance levels to avoid drug accumulation.
- Keppra XR should be swallowed whole; tablets should not be crushed, chewed or broken to maintain extended-release properties.
- Spritam tablets for suspension provide an alternative for patients unable to swallow tablets, including some pediatric populations.

Mechanism Of Action

Levetiracetam, the active ingredient in Keppra XR, exerts its antiepileptic effect via a unique mechanism distinct from traditional sodium channel blockers or GABAergic agents. Its primary molecular target is the synaptic vesicle protein 2A (SV2A), a membrane glycoprotein found ubiquitously in presynaptic vesicles of neurons. Binding of levetiracetam to SV2A modulates synaptic vesicle exocytosis and neurotransmitter release, thereby stabilizing neuronal activity and preventing hyper synchronization associated with seizures.

At the cellular level, levetiracetam modifies neurotransmitter release by altering vesicle trafficking and availability rather than directly modifying ion channel activity. This modulation reduces excitatory neurotransmission while preserving inhibitory signaling, contributing to its broad spectrum of anticonvulsant activity without the sedative or cognitive side effects common to other agents.

Biochemically, levetiracetam does not inhibit or enhance the activity of the GABA_A receptor or other major neurotransmitter receptors significantly; instead, it influences calcium signaling pathways indirectly through its SV2A interaction. This results in decreased neuronal excitability and seizure threshold elevation.

Clinical implications show that levetiracetam is effective for partial-onset, myoclonic, and generalized tonic-clonic seizures, with a favorable safety profile owing to its distinct mechanism that avoids many drug interactions and side effects associated with other antiepileptics. Comparative studies indicate superior tolerability versus agents such as carbamazepine and phenytoin, with a low risk of cognitive impairment. Ongoing research continues to explore SV2A as a therapeutic target for seizure control and potential neuroprotective effects in epilepsy treatment.

Pharmacological Actions

Selective binding to synaptic vesicle protein 2A (SV2A) modulating neurotransmitter release.
Inhibition of neuronal hyperexcitability by stabilizing synaptic transmission.
Reduction in the spread of seizure activity within the brain.
Low plasma protein binding minimizes drug interactions.
Minimal hepatic metabolism reduces hepatic enzyme induction or inhibition.
Broad-spectrum anticonvulsant activity effective in various seizure types.
No significant interaction with GABAergic, glutamatergic, or sodium ion channels.
Renal excretion allows predictable elimination and dosing adjustments in renal impairment.
Absence of sedative, cognitive, or motor impairments at therapeutic doses.
Well-tolerated in both monotherapy and polytherapy settings.
Rapid onset of action with steady plasma levels from extended-release formulation.
Low risk of pharmacokinetic drug-drug interactions due to unique metabolic pathways.

Therapeutic Or Clinical Uses

Management of partial-onset seizures in adults and pediatric patients 1 month of age and older.
Treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy aged 12 years and older.
Control of primary generalized tonic-clonic seizures in patients aged 6 years and older.
Adjunctive therapy for epilepsy to improve seizure control.
Use in patients who require once-daily dosing for improved compliance (Keppra XR).
Treatment of epilepsy in both newly diagnosed and refractory cases.
Suitable for monotherapy and adjunct therapy in partial seizures.
Management of seizures where other antiepileptic drugs are contraindicated or poorly tolerated.
Useful in patients with hepatic impairment due to minimal hepatic metabolism.
Alternative for patients experiencing side effects from traditional antiepileptics.
Treatment option for patients with renal dose adjustments requirements.
Prescribed in pediatric seizure disorders with appropriate weight-based dosing.

Side Or Adverse Effects

Aggressiveness, irritability, or mood changes including anxiety and anger.
Drowsiness, fatigue, somnolence, or unusual tiredness.
Dizziness or loss of coordination affecting balance and motor skills.
Headache and general discomfort or malaise.
Infections such as upper respiratory tract infections and cough.
Nausea, vomiting, diarrhea, and loss of appetite.
Behavioral abnormalities including agitation, depression, psychotic symptoms.
Skin reactions ranging from mild rash to rare but severe Stevens-Johnson syndrome and toxic epidermal necrolysis.
Suicidal ideation or thoughts of self-harm requiring immediate medical attention.
Laboratory abnormalities such as leukopenia or thrombocytopenia in rare cases.
Respiratory symptoms including hoarseness and bronchitis.
Musculoskeletal complaints including muscle pain, stiffness, and joint pain.
Rare occurrences of angioedema or anaphylaxis requiring urgent care.
Blistering, peeling, or sloughing of skin indicating serious hypersensitivity.
Rare neurological adverse effects such as seizures paradoxically or movement disorders.

Precautions

Monitor mood and behavior closely due to risk of depression, anxiety, or suicidal thoughts.
Do not discontinue therapy abruptly to avoid precipitating seizures.
Dose adjustments necessary in patients with moderate to severe renal impairment.
Use caution in patients with a history of mental illness or psychiatric disorders.
Pregnancy registry enrollment is recommended for pregnant patients receiving levetiracetam.
Advise patients regarding potential dizziness or somnolence and caution when driving or operating machinery.
Inform healthcare providers and dentists of levetiracetam use prior to procedures or new medications.
Regular monitoring during treatment for seizure control efficacy and adverse effects.
Use with caution in elderly patients due to possible renal function decline.
Ensure adherence to prescribed dosing schedule to maintain seizure control.
Assess liver and kidney function prior to and during treatment as clinically indicated.
Evaluate for serious skin reactions at onset of rash or hypersensitivity symptoms.
Consider potential interactions with drugs that increase risk of bleeding or CNS depression.
Advise breastfeeding women on potential risks vs benefits until more data available.
Avoid use in pediatric patients under specified age or weight limits without medical supervision.

Warnings

Risk of serious behavioral reactions including suicidal ideation and psychosis.
Potential for life-threatening hypersensitivity reactions such as anaphylaxis and angioedema.
Warning against sudden discontinuation to prevent seizure exacerbation.
Serious skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis can occur.
May cause somnolence and dizziness; patients should avoid hazardous activities until effects are known.
Use is not recommended in patients with moderate to severe renal impairment without dose adjustment.
Potential worsening of depression, anxiety, or other psychiatric disorders during therapy.
Patients should be monitored closely during the initial months of treatment for emergent side effects.
Keppra XR tablets should not be chewed, crushed, or broken to prevent dose dumping.
Risk of hematologic abnormalities warrants periodic blood count monitoring if clinically indicated.
Use caution when combining levetiracetam with anticoagulants or other drugs affecting CNS.
Pregnancy use involves weighing risks; use only if clearly needed under medical supervision.
May affect results of certain laboratory tests, alert healthcare providers accordingly.
Patients and caregivers should be informed of signs and symptoms requiring immediate medical attention.

Contraindication

Known hypersensitivity to levetiracetam or any component of the formulation.
History of severe allergic reactions such as anaphylaxis to levetiracetam.
Use in pediatric patients outside approved age ranges without appropriate clinical justification.
Use with caution or contraindicated in patients with severe renal impairment without dose adjustment.
Contraindicated to crush or chew extended-release tablets due to altered drug release kinetics.
Known history of Stevens-Johnson syndrome or toxic epidermal necrolysis related to levetiracetam.
Concurrent use with drugs that are contraindicated due to severe interaction risks (as determined by physician).
Patients demonstrating intolerable adverse reactions precluding continuation of therapy.
Established severe psychiatric disorders not controlled or exacerbated by the drug.

Drug Interactions

Apixaban: Potential interaction requiring dose adjustment or monitoring of anticoagulant effect.
Calcifediol: Co-administration generally not recommended without medical supervision due to unknown interactions.
Dabigatran Etexilate Mesylate: Possible interaction; close monitoring advised if co-prescribed.
Edoxaban: Use caution; increased risk of bleeding may occur when used concomitantly.
Levoketoconazole: Use is usually not recommended due to potential pharmacodynamic or pharmacokinetic interactions.
Methotrexate: Interaction may increase toxicity; monitoring is needed when used together.
Orlistat: May alter absorption or plasma levels of levetiracetam; dose adjustments may be required.
Rivaroxaban: Combined use may elevate bleeding risk; clinical monitoring essential.
Carbamazepine: May increase side effect risk; dose adjustments and monitoring advised.
Ginkgo: Potential increased risk of bleeding or seizure threshold alteration; avoid or monitor closely.
Minimal hepatic enzyme induction or inhibition minimizes many common drug interactions.
Renal clearance dependence requires caution with other nephrotoxic agents.
No significant interaction noted with commonly used antiepileptics such as valproate or lamotrigine.
In vitro studies confirm negligible cytochrome P450 involvement.
Patients should report all concomitant medications to healthcare providers to prevent adverse interactions.

Preparations Of The Drug

Keppra XR Extended-Release Tablets: film-coated tablets designed for once-daily dosing, strengths typically at 500 mg and 750 mg.
Keppra Immediate-Release Tablets: available in 250 mg, 500 mg, 750 mg, and 1000 mg formulations for twice-daily dosing.
Spritam Tablets for Suspension: rapidly disintegrating tablets in doses of 250 mg, 500 mg, 750 mg, and 1000 mg for ease of administration.
Keppra Oral Solution: 100 mg/mL suspension for patients who cannot swallow tablets, suitable for all ages including infants.
Elepsia XR: an alternative extended-release formulation with similar pharmacokinetic profile and clinical utility.
Roweepra and Roweepra XR: Other branded formulations equivalent to immediate and extended-release levetiracetam respectively.
All preparations require prescription and are intended for epilepsy management under medical supervision.
Formulations are designed to cater to diverse patient needs including pediatric, geriatric, and those with swallowing difficulties.
Extended-release and suspension forms assist in compliance and flexibility of dosing regimens.
Tablet preparations are packaged to protect against moisture and must be stored at room temperature.
Oral solutions come with dosing devices like syringes or cups to ensure accurate dosing.